BioSpace News Archive

Cell lines are a one of the key tools that are used for studying and researching the normal biochemistry and physiology of the cells.

The world cardiovascular ultrasound system market is foretold to take the first flight to maintaining a substantial progress with innovations and collaborations encouraged globally.

Barotrauma constitutes injuries instigated due to changes in pressure of air or water. These changes in pressure can take place during flights and deep sea diving.

Acid sphingomyelinase is one of the enzymes from the family sphingomyelinase. It is an enzyme responsible for the development of phosphorylcholine and ceramide molecules through the breakdown of sphingomyelin.

InnoCare Pharma and Keymed Biosciences jointly announced that the first patient in China has been dosed in clinical trial of CM355, a CD20xCD3 bispecific antibody developed by a joint venture between the two companies, for the treatment of CD20+ B-cell malignancies.

MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced the publication of “Uncovering the high prevalence of bacterial burden in surgical site wounds with point-of-care fluorescence imaging"1 in International Wound Journal.

NuGen Medical Devices Inc. is pleased to announce that it has entered into an exclusive distribution agreement with Intermediq Holdings Ltd., a well-established medical distribution company in Sri Lanka.

Osmotica Pharmaceuticals plc announced today that Brian Markison, Chief Executive Officer and James “JD” Schaub, Chief Operating Officer, will host a video webcast to discuss recent UPNEEQ® trends, pending expansion into the medical aesthetics market and other general business updates.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the commercial availability of its recently approved product, vasopressin, an A-rated generic alternative to Vasostrict with 180 days of marketing exclusivity.

ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced that it has initiated a program to develop monoclonal antibodies to treat schizophrenia and other chronic mental illnesses.